LifeScience Emerging Biotech
Ono Pharma Reports Positive Phase 2 Signals for ONO-2808 in Multiple System Atrophy
Efficacy signals were observed in an interim analysis of a Phase 2 clinical trial for ONO-2808, a S1P5 receptor agonist Phase 2 clinical trial was con...
October 13, 2025 | News
biomodal Launches Global Certified Service Provider Network to Expand Access to duet Multiomics Technology
biomodal, an omics-based life sciences technology and analytics company, announced it has launched a Certified Service Provider (CSP) program with pa...
October 10, 2025 | News
Anasens Partners with MAVAND Solutions to Expand DrugAsens™ Rapid Oral-Fluid Drug Testing Across Europe and Australia
Anasens Inc., a developer of rapid, connected point-of-care detection tools, announced it has signed a distribution agreement with MAVAND Soluti...
October 08, 2025 | News
Celaid Therapeutics Secures ¥1.05 Billion in Series B First Close to Advance Next-Generation Stem Cell Therapies
Celaid Therapeutics Inc. announced the successful completion of the 1st Close of its Series B financing round, raising JPY 1.055 billion (US...
October 08, 2025 | News
RoosterBio and Secretome Therapeutics Achieve Commercial-Scale Production Milestone for Lead Cell Therapy STM-01
RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and...
October 07, 2025 | News
ExQor Technologies Prepares for Clinical Trials of Regenerative Platform Aiming to Reverse Alzheimer’s Damage
ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine pla...
October 06, 2025 | News
Nanyang Biologics to Go Public Through Business Combination with RF Acquisition Corp II Valued at 1.5 Billion USD
Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform ...
October 03, 2025 | News
WuXi XDC Co-Hosts 2025 BPD Singapore Summit Showcasing Innovation in Bioconjugates and Global Biopharma Collaboration
The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully conclude...
September 30, 2025 | News
Galux Validates AI-Driven Platform with Atomic-Level Precision in De Novo Antibody Design
Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Finding...
September 23, 2025 | News
CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS
CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...
September 22, 2025 | News
EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...
September 18, 2025 | News
Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer
Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...
September 16, 2025 | News
BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...
September 16, 2025 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
